RecruitingNCT07932002Updated Nov 12, 2026

Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens

A Phase 4 interventional study of Ruconest in Post SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome and Post-Viral Disorder (Disorder), sponsored by IMMUNOe Research Centers. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by IMMUNOe Research Centers · Phase 4, Interventional, and Treatment

From the registry’s dates

Registered 1 year after the study started (first participant enrolled Nov 2025, registered Nov 2026).
Started Nov 2025; still recruiting 1 year later.

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Phase: Phase 4
Study type: Interventional
Enrollment: 30
Allocation: Not applicable
Ages: 18 Years to 90 Years
Sex: All

Where this study stands

Counted across the records on this site · 2026-11-12

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment: 951st of 1,321; 30 · median 91
Started: 2025; with 45 others
Phase 4: 60 of 1,859; 6 open now
Primary completion: 2027-07; later than 135 of 208 live
Registered: 1,859th of 1,859; by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 951st largest by planned enrollment of the 1,321 interventional ones that give a count, is one of 46 that started in 2025, is one of 60 in phase 4, reaches primary completion later than 135 of the 208 other live ones, and was the 1,859th registered.

COVID-19

7,992 studies on the registry are indexed under COVID-19; 466 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

RecruitingPhase 4NCT07863635
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
RecruitingNCT07149428
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
RecruitingPhase 3NCT07743580
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
RecruitingPhase 2NCT07808697
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
RecruitingPhase 3NCT07798648
A Study of COVID-19 Vaccine(s) in Children and Adults
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers

114 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Who runs the 1,859 studies in COVID-19 with a site in United States

638 of 1,859 have an industry lead sponsor. The 10 most frequent:

National Institute of Allergy and Infectious Diseases (NIAID)59 · 4 open

Pfizer44 · 3 open · industry

Duke University37 · 4 open

Mayo Clinic28 · 3 open

University of Pennsylvania26

ModernaTX, Inc.25 · 3 open · industry

Stanford University25 · 1 open

Columbia University22 · 2 open

BioNTech SE21 · 2 open · industry

University of Minnesota21

IMMUNOe Research Centers in COVID-19

IMMUNOe Research Centers is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

IMMUNOe Research Centers has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.

Its COVID-19 studies →

Coming up

85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:

Study	Primary completion
NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study	2026-12
NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults	2027-04-21
NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised	2027-09-28
NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease	2027-10-01
NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen	2027-11-04

All 85 — sign in →

Add all 85 to your calendar (.ics) → With an account.

What changed since 2026-09-25

Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:

Newly registered 7

NCT079320022026-11-12Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
NCT079001392026-10-28A Study to Learn About COVID-19 Antivirals in People With SARS-CoV-2 Infection From 2023-2026
NCT078752702026-10-15Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
NCT078714482026-10-13Flu COVID Vaccine Views
NCT078636352026-10-07A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations

2 more — sign in →

Started recruiting 6

NCT078086972026-10-29A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
NCT072871372026-10-28Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
NCT078636352026-10-27A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
NCT078615422026-10-15Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
NCT071494282026-10-09Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

1 more — sign in →

Stopped 4

NCT070862222026-10-23TERMINATEDEfficacy and Safety of NVX-CoV2705
NCT069501772026-10-19TERMINATEDPancoronavirus Vaccine Study in Healthy Adults
NCT044014752026-09-30TERMINATEDA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
NCT046347992026-09-25TERMINATEDStudy To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Results posted 4

NCT043350842026-11-04A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
NCT067446602026-11-03Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
NCT048291882026-10-26Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia
NCT046347992026-09-25Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Primary completion moved 36

NCT051720112026-11-122027-04-01 → 2028-12-31Understanding the Long-term Impact of COVID on Children and Families
NCT051026562026-11-102027-02-02 → 2026-11-03Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic
NCT039636222026-11-102026-06 → 2027-06Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
NCT065059932026-11-062027-09 → 2027-12Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
NCT054252642026-11-062027-01-30 → 2027-09-30Home-Based Exercise Tele-Rehabilitation After COVID-19

31 more — sign in →

This tab as a report to print or save as PDF → With an account.

Watch this landscape Download CSV Narrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.

Study summary

Assessment of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens

Read the detailed description

This study will last approximately 30 weeks including 24 infusions total, each one week apart. This is an open label extension study aimed to investigate the continued use of RUCONEST in a post-SARS-CoV-2 population who experienced neurological symptoms both in patients who have participated in the previous trial (NCT04705831) as well as RUCONEST-naive participants.

Conditions studied

Post SARS-CoV2 (COVID-19)
Post-Viral Fatigue Syndrome
Post-Viral Disorder (Disorder)
COVID - 19

Browse trials for

Keywords

post-viral fatigue syndrome
Post-COVID Symptoms

Who can participate

Ages eligible: 18 Years to 90 Years
Sexes eligible: All
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18 and older, male or female
Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations.
Patients who were involved in the previous study with defined post-COVID neurologic symptoms.
New patients who have been diagnosed with post-COVID neurologic symptoms.

Exclusion criteria

Exclusion Criteria:

Receiving any form of C1-INH therapy, either acute or prophylactic treatment
History or suspicion of allergy to rabbits
Neurological conditions related to injury
Neuropathy related to diabetes
Abnormal kidney or liver enzymes
History of thrombotic stroke
Participants who are pregnant or lactating
Largely incapacitated or bed-ridden
Currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued within 30 days of study entry from any other clinical study involving and investigational product.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Study design

Phase: Phase 4
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 30 participants (estimated)

Study arms

Active comparator
Ruconest
IV Ruconest
Drug: Ruconest

Interventions

DrugRuconest
IV Ruconest

What researchers measure

Primary outcomes

Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 0
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 5
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 9
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 13
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 17
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 21
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function - Adult
Time frame: Week 25
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 0
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 5
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 9
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 13
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 17
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 21
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: Week 25
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 0
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 5
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 9
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 13
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 17
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 21
Neuropsychological Measures (BDI II)
Beck Depression Inventory (BDI II)
Time frame: Week 25
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 0
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 5
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 9
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 13
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 17
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 21
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 25
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 0
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 5
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 9
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 13
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 17
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 21
Patient-Rated Questionnaire (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 25
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 0
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 5
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 9
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 13
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 17
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 21
Patient-Rated Questionnaire (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 25
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 0
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 5
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 9
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 13
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 17
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 21
Patient-Rated Questionnaire (HIT)
Headache Impact Scale (HIT)
Time frame: Week 25
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 0
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 5
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 9
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 13
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 17
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 21
Patient-Rated Questionnaire (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 25
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 0
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 5
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 9
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 13
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 17
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 21
Patient-Rated Questionnaire (SF)
SF McGill Pain Questionnaire
Time frame: Week 25
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 0
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 5
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 9
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 13
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 17
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 21
Patient-Rated Questionnaire (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 25
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 0
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 5
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 9
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 13
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 17
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 21
Patient-Rated Questionnaire (SF-36)
SF-36
Time frame: Week 25
Neurological Exam
Complete neurological examination
Time frame: Week 0
Neurological Exam
Complete neurological examination
Time frame: Week 5
Neurological Exam
Complete neurological examination
Time frame: Week 9
Neurological Exam
Complete neurological examination
Time frame: Week 13
Neurological Exam
Complete neurological examination
Time frame: Week 17
Neurological Exam
Complete neurological examination
Time frame: Week 21
Neurological Exam
Complete neurological examination
Time frame: Week 25

Study locations

1 of 1 sites recruiting

IMMUNOe Research Centers
Centennial, Colorado 80112, United States
Recruiting
- Maureen Collins · Contact · mcollins@immunoe.com · 303-771-9000
- Isaac Melamed, MD · Principal investigator
- J. Lynn Williams, MD · Sub investigator
Recruiting

Timeline

1 registry update since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 44 industry-sponsored phase 4 interventional studies under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 20 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered: Nov 6, 2026
First posted: Nov 12, 2026
StartActual: Nov 5, 2025
Primary completionEst.: Jul 31, 2027
CompletionEst.: Oct 29, 2027
Last update: Nov 12, 2026

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

Registered

First appeared on the registry. No changes since

Nov 12, 2026

Show all 1 update

Nov 12, 2026
First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07932002
Lead sponsor: IMMUNOe Research Centers
Responsible party: Isaac Melamed, MD (Site Principal Investigator, IMMUNOe Research Centers) — Principal investigator
First posted: Nov 12, 2026
Start date: Nov 5, 2025
Primary completion: Jul 31, 2027 (estimated)
Completion: Oct 29, 2027 (estimated)
Last update: Nov 12, 2026

Oversight

Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Conestat alfa

Other studies in this condition

COVID-19 →

Other studies from this sponsor

IMMUNOe Research Centers

Start the discussion